Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”).

If you suffered a loss on your Y-mAbs investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Y-mAbs-Therapeutics-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On April 1, 2022, the Company announced that it had resubmitted its Biologics License Application (“BLA”) for omburtamab for the treatment of pediatric patients with CNS from neuroblastoma, following several meetings with the U.S. Food and Drug Administration (“FDA”) to address deficiencies identified in the agency’s 2020 refusal to file letter in response to Y-mAbs’s previous BLA.

On October 26, 2022, the FDA released its briefing document in advance of its Advisory Committee meeting to discuss the omburtamab BLA. The briefing document identified three key issues regarding the submitted data, which led analysts to conclude that Y-mAbs had resubmitted the BLA prior to reaching agreement with the FDA regarding the content of the application.

On this news, Y-mAbs’s stock price fell $4.16, or 27.4%, to close at $11.01 per share on October 26, 2022, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants misrepresented to investors that, pursuant to a series of meetings and other communications between the Company and the FDA, that progress was being made that would align with the FDA’s requirement to demonstrate substantial evidence of effectiveness, sufficient for approval of omurtamab, through adequate and well-controlled studies.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Y-mAbs common stock during the Class Period, you may move the Court no later than March 20, 2023 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005343/en/